Carregant...
Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes
Background: SAR342434 (SAR-Lis) is a biosimilar (follow-on) of insulin lispro (Humalog(®); Ly-Lis). Two randomized, controlled, open-label, parallel-group, phase 3 studies were conducted to compare the efficacy and safety of SAR-Lis and Ly-Lis, both in combination with insulin glargine (Lantus(®))....
Guardat en:
| Publicat a: | Diabetes Technol Ther |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Mary Ann Liebert, Inc.
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5771536/ https://ncbi.nlm.nih.gov/pubmed/29355435 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/dia.2017.0373 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|